Richard B Roden

Title: Innovations of Richard B Roden

Introduction

Richard B Roden is an accomplished inventor based in Severna Park, MD (US). He holds a total of 4 patents that contribute significantly to the field of cancer research and treatment. His work focuses on developing innovative therapeutic agents that target specific cancer pathways.

Latest Patents

One of his latest patents is for a bis-benzylidine piperidone proteasome inhibitor with anticancer activity, known as RA190. This compound covalently binds to the ubiquitin receptor RPN13 (ADRM1) in the 19S regulatory particle, inhibiting proteasome function and leading to the rapid accumulation of polyubiquitinated proteins. Notably, multiple myeloma lines, even those resistant to bortezomib, showed sensitivity to RA190 through ER stress-related apoptosis. RA190 also stabilizes targets of the human papillomavirus (HPV) E6 oncoprotein and preferentially kills HPV-transformed cells. After administration in mice, RA190 distributed to plasma and major organs, effectively inhibiting proteasome function in skin and muscle. The compound demonstrated profound effects in reducing the growth of multiple myeloma and ovarian cancer xenografts, while oral treatment with RA190 retarded HPV+ syngeneic mouse tumor growth without impacting spontaneous HPV-specific CD8+ T cell responses. This suggests a promising therapeutic potential for RA190 in treating multiple myeloma, cervical, and ovarian cancers.

Career Highlights

Richard B Roden has had a distinguished career, contributing to significant advancements in cancer research. He has worked with prestigious institutions such as The Johns Hopkins University and the National Institutes of Health, a component of the US Department of Health & Human Services. His research has been pivotal in developing new cancer therapies.

Collaborations

Throughout his career, Roden has collaborated with notable colleagues, including Ravi K Anchoori and Balasubramanyam Karanam. These collaborations have further enhanced the impact of his research and innovations.

Conclusion

Richard B Roden's contributions to cancer research through his innovative inventions, particularly the bis-benzylidine piperidone RA190, highlight his role as a significant figure in the field. His work continues to pave the way for new therapeutic strategies in oncology.